The US State of California becomes the first State to enact legislation rendering certain pharmaceutical patent litigation settlement agreements presumptively anticompetitive

This article has been nominated for the 2020 Antitrust Writing Awards. Click here to learn more about the Antitrust Writing Awards.

On October 7, 2019, California became the first state to enact legislation— Assembly Bill 824 (“AB 824”)—rendering certain pharmaceutical patent litigation settlement agreements presumptively anticompetitive. [1] This alert provides a brief summary of some of the key provisions as written; the final implications of this statute await judicial review. Reverse Payment Settlements Including “Anything of Value” Presumed Illegal The settlement agreements subject to the new law, sometimes referred to pejoratively as “reverse payment” or “pay for delay” agreements, typically resolve Hatch-Waxman patent litigation [2] in which a generic pharmaceutical manufacturer has challenged a patent covering a brand pharmaceutical manufacturer’s drug product, and in which a plaintiff or government enforcer

L'accès à cet article est réservé aux abonnés

Déjà abonné ? Identifiez-vous

L’accès à cet article est réservé aux abonnés.

Lire gratuitement un article

Vous pouvez lire cet article gratuitement en vous inscrivant.

 

Version PDF

Auteurs

Citation

Mark J. Gidley, Noah A. Brumfield, Jack E. Pace, Kristen O'Shaughnessy, Dan Grossbaum, Bryan D. Gant, The US State of California becomes the first State to enact legislation rendering certain pharmaceutical patent litigation settlement agreements presumptively anticompetitive, 7 octobre 2019, e-Competitions October 2019, Art. N° 96882

Visites 117

Tous les numéros

  • Latest News issue 
  • Tous les News issues
  • Latest Special issue 
  • Tous les Special issues